Zusammenfassung
In den letzten Jahren hat sich gezeigt, daß die kardialen Wirkungen kreislaufaktiver Substanzen sehr differenziert hinsichtlich bestehender Erkrankungen der Patienten, ihres Alters und einer eventuellen Begleitmedikation betrachtet werden müssen. Wirkungen und Nebenwirkungen treten von Fall zu Fall verschieden in Erscheinung. Pharmakologische Untersuchungen an gesunden jungen Tieren können neben den speziesbedingten Unterschieden meist nicht die Wirkungen erfassen, die bei Patienten z. B. mit unterschiedlichen Grundkrankheiten auftreten [2]. Sensibilisierungen und Desensibilisierungen von Rezeptoren und zellulären Enzymen sowie Toleranzentwicklungen, die zu erhöhten oder verminderten Empfindlichkeiten gegenüber Katecholaminen und anderen Medikamenten führen, spielen eine zunehmende Rolle bei unseren Entscheidungen. Therapiekonzepte haben zu berücksichtigen, daß sich Wirkungen und sogar Wirkungsmechanismen bei verschiedenen Krankheitszuständen wesentlich ändern.
This is a preview of subscription content, log in via an institution.
Buying options
Tax calculation will be finalised at checkout
Purchases are for personal use only
Learn about institutional subscriptionsPreview
Unable to display preview. Download preview PDF.
Literatur
Böhm M, Diet F, Feiler G, Kemkes B, Kreuzer E, Weinhold C, Erdmann E (1988) Subsensitivity of the failing human heart to isoprenaline and milrinone is related to 3-adrenoceptor downregulation. J Cardiovasc Pharmacol 12: 726–732
Böhm M, Diet F, Pieske B, Erdmann E (1989) Screening of positive inotropic agents in isolated cardiac preparations from different sources. J Pharmacol Meth 699: 33–44
Böhm M, Pieske B, Schnabel P, Schwinger RGH, Kemkes B, Klövekorn WP, Erdmann E (1989) Reduced effect of dopexamine on force of contraction in the failing human heart despite preserved 02-adrenoceptor subpopulation. J Cardiovasc Pharmacol 14: 549–559
Böhm M, Gierschik P, Jakobs KH, Pieske B, Schnabel P, Ungerer M, Erdmann E (1990) Increase of Gia in human hearts with dilated but not ischemic cardiomyopathy. Circulation 82: 1249–65
Böhm M, Morano I, Pieske B, Rüegg JC, Wankerl M, Zimmermann R, Erdmann E (1991) Contribution of cAMP-phosphodiesterase inhibition and sensitization of the contractile proteins for calcium to the inotropic effect of pimobendan in the failing human myocardium. Circ Res 68: 689–701
Bristow MB, Ginsburg R, Minobe W, Cubicotti RS, Sageman WS, Lurie K, Billingham ME, Harrison DC, Stinson EB (1982) Decreased catecholamine sensitivity and beta-adrenergicreceptor density in failing human hearts. N Engl J Med 307: 205–211
Brodde OE, (1991) f31- and 132-adrenoceptors in the human heart. Properties, function and alterations in chronic heart failure. Pharmacol Rev 43:203–242
Cohn JN, Levine TB, Olivari MT, Garberg V, Lura D, Francis GS, Simson AB, Rector T (1984) Plasma noradrenaline as a guide to prognosis in patients with chronic congestive heart failure. N Engl J Med 311: 819–823
DiBianco R, Shabetai R, Kostuk Wet al. (1989) A comparison of oral milrinone, digoxin, and their combination in the treatment of patients with chronic heart failure. N Engl J Med 320: 677–683
Dies F, Krell MJ, Whitlow P, Liang CH, Goldenberg I, Applefeld MM, Gilbert EM (1986) Intermitttent dobutamine in ambulatory outpatients with chronic cardiac failure. Circulation 74 (Suppl II): II - 138
Feldmann AM, Cates AE, Veazey WB, Hershberger RE, Bristow MR, Baughman KL, Baumgartner WA, van Dop C (1988) Increase of the 40,000-mol wt pertussis toxin substrate ( G protein) in the failing human heart. J Clin Invest 82: 189–197
Kubo SH, Gollub S, Bourge R et al. (1992) Beneficial effects of pimobedan on exercise tolerance and quality of life in patients with heart failure. Circulation 85: 942–949
Massie BM, Berk MR, Brozena S, Elkayam U, Plehn J, Kukin M, Murphy B, Neuberg G, Steingart R, DeHaan H (1992) Can further benefit be achieved by adding a vasodilatator to triple therapy in CHF; results of the flosequinan-ACE inhibitor trial (FACET)? AHA I-645 (Abstr)
Neumann J, Schmitz W, von Meyerinck L, Scholz HJ, Döring V, Kalmar P (1988) Increase in myocardial Gi-proteins in heart failure. Lancet II: 936–937
Packer M, Carver JR, Rodeheffer RJ et al. (1991) Effect of oral milrinone on mortality in severe chronic heart failure. N Engl J Med 325: 1468–1475
Packer M, Pitt B (1992) Efficacy of flosequinan in patients with heart failure who are withdrawn from therapy with converting-enzyme inhibitors: a doubleblind controlled study. Circulation 86 (Suppl I): I - 644
Schwinger RHG, Böhm M, Erdmann E (1990) Evidence against spare or uncoupled 13-adrenoceptors in the human heart. Am Heart J 119: 899–904
Schwinger RGH, Böhm M, Erdmann E (1990) Effectiveness of cardiac glycosides in human myocardium with and without „downregulated“ 3-adrenoceptors. J Cardiovasc Pharmacol 15: 692–697
Schwinger RHG, Böhm M, La Rosée K, Schmidt U, Schulz C, Erdmann E (1992) Na-channel activations increase cardiac glykoside sensitivity in failing human myocardium. J Cardiovasc Pharmacol 19: 554–561
Schwinger RHG, Böhm M, Uhlmann R, Erdmann E (1992) BDF9148 and Quabain are effective to restore the normal force-frequency relationship in failing human myocardium. Circulation 86 (Suppl I): I - 284
Ungerer M, Böhm M, Elce JS, Erdmann M, Lohse MJ (1993) Altered expression of 3-adrenergic receptor kinase and 01-adrenergic receptors in the failing human heart. Circulation 87: 454–463
Uretsky BF, Jessup M, Konstam A et al. (1990) Multicenter trial of oral enoximone in patients with moderate to moderately severe congestive heart failure. Circulation 82: 774–780
Waagstein F, Caidahl K, Wallentin I, Bergh CH, Hjalmarson A (1989) Long-term 3-blockade in dilated cardiomyopathy. Circulation 80: 551
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Erdmann, E., Schwinger, R.H.G., Böhm, M. (1995). Klinisch-pharmakologische Aspekte kardioaktiver Pharmaka. In: Ahnefeld, F.W., Dick, W., Erdmann, E. (eds) Herz- und kreislaufwirksame Medikamente in Anästhesie, Intensiv- und Notfallmedizin. Klinische Anästhesiologie und Intensivtherapie, vol 47. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-78777-5_2
Download citation
DOI: https://doi.org/10.1007/978-3-642-78777-5_2
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-57634-1
Online ISBN: 978-3-642-78777-5
eBook Packages: Springer Book Archive